Evidence map›Paper›PMID 39565117›Full record

ArticleAntimicrobial agents and chemotherapy2025

LDC000067, a CDK9 inhibitor, unveils promising results in suppressing influenza virus infections

Mingxin Zhang, Xiaoqin Lian, Yarou Gao, Lefang Jiang, Zhuogang Li, Haonan Zhang, Yue Su, Qun Peng, Xulin Chen

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. CMGC Kinases in Viral Infection and Human Disease.Pathogens (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mingxin ZhangDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
Xiaoqin LianDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
Yarou GaoDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
Lefang JiangDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
Zhuogang LiDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
Haonan ZhangDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
Yue SuDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
Qun PengDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
Xulin ChenDepartment of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.ORCID 0000-0002-4479-1145

Funding

Department of Education of Guangdong Province (DEGP) 88020032
6 · The paper itself

Abstract

Influenza virus infections continue to pose a significant threat to public health. Current anti-influenza drugs target viral proteins; however, the emergence of resistant strains has hampered their effectiveness. Fortunately, as with most viruses, influenza virus depends on various host factors during its replication cycle and in pathogenicity. Therefore, the manipulation of key host factors for viral replication to combat influenza has garnered increased attention due to its lesser tendency to induce viral mutation. Cyclin-dependent kinases (CDKs) are a family of protein kinases that regulate various cellular processes, including the cell cycle and transcription. While the specific involvement of CDKs in the transcription of influenza virus genes is less extensively studied than their roles in the cell cycle, some evidence suggests their potential contributions as anti-influenza drugs. Here, we report that LDC000067 (LDC), a highly specific CDK9 inhibitor, not only strongly suppressed influenza virus replication

Indexed as

Antiviral AgentsCyclin-Dependent Kinase 9Influenza A Virus, H1N1 SubtypeOrthomyxoviridae InfectionsProtein Kinase InhibitorsA549 CellsAnimalsDogsFemaleHumansInfluenza, HumanMadin Darby Canine Kidney CellsMiceMice, Inbred BALB CVirus ReplicationAntiviral AgentsCDK9 protein, humanCyclin-Dependent Kinase 9Protein Kinase Inhibitorsantiviral targetCDK9LDC000067nuclear import of vRNPsRNA transcription

Identifiers

PMID39565117
PMCPMC11784216

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.